The Moyamoya Disease causes treatment protocol
Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing or occlusion of the internal carotid arteries and their main branches at the base of the brain. This constriction leads to the development of a network of fragile, abnormal blood vessels attempting to compensate for reduced blood flow, which on angiography appears as a “puff of smoke,” hence the name “moyamoya” in Japanese. The disease affects both children and adults, often presenting with ischemic strokes, transient ischemic attacks, or hemorrhages, depending on the extent and location of vessel narrowing and collateral formation.
The underlying cause of moyamoya disease remains largely unknown, although genetic factors are believed to play a role, especially in familial cases. Certain ethnic groups, such as Japanese, Koreans, and Chinese, show higher prevalence rates. Environmental factors and autoimmune conditions may also contribute to its development, but definitive causes are yet to be fully elucidated.
Treatment of moyamoya disease aims primarily at preventing stroke and restoring adequate cerebral blood flow. The approach can be divided into medical management and surgical intervention. Medical therapy includes antiplatelet medications, such as aspirin, to reduce the risk of thrombotic events. However, these drugs do not address the underlying vascular abnormalities and are mainly supportive. Consequently, surgical revascularization remains the cornerstone of treatment, especially in symptomatic patients.
Surgical procedures for moyamoya disease are designed to enhance blood flow to affected areas of the brain by creating new pathways for circulation. These procedures are broadly categorized into direct and indirect revascularization techniques. Direct revascularization involves anastomosing a scalp artery, such as the superficial temporal artery, directly to a cerebral artery, like the middle cerebral artery. This provides immediate blood flow augmentation. Indirect revascularization, such as encephaloduroarteriosynangiosis (EDAS) or encephalomyosynangiosis (EMS), involves placing vascularized tissue—such as the scalp or muscle—against the brain surface, encouraging the development of new collateral vessels over time.
The choice of surgical method depends on patient age, disease severity, and surgeon expertise. In children, indirect methods are often preferred due to their less invasive nature, while adults may benefit more from direct bypass procedures. Combining both techniques, known as combined revascularization, can also be employed for optimal results.
Preoperative assessment includes detailed cerebral angiography to delineate the extent of arterial narrowing and collateral formation. Postoperative care involves close monitoring for potential complications like hemorrhage, ischemia, or hyperperfusion syndrome. Long-term follow-up with imaging is essential to ensure the durability of revascularization and to detect any disease progression.
While surgical intervention significantly reduces the risk of future strokes, it does not cure moyamoya disease. Patients require ongoing neurological surveillance and management of risk factors. Advances in neuroimaging and surgical techniques continue to improve outcomes, emphasizing the importance of early diagnosis and comprehensive treatment strategies.
In summary, moyamoya disease is a complex cerebrovascular condition that necessitates a multidisciplinary approach for optimal management. Surgical revascularization remains the mainstay of treatment, aiming to restore cerebral blood flow, prevent strokes, and improve quality of life for affected individuals.